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We read with great interest the recently published work of
Malpas et al. (2020) in which the authors identified clinical
markers of patients with aggressive multiple sclerosis in a co-
hort of relapsing remitting multiple sclerosis (RRMS)
patients with 10 years of follow-up. The authors followed
the definition a confirmed Expanded Disability Status Scale
(EDSS) score 56.0 within 10 years of disease onset, which
was initially applied by Tintore et al. (2019) to a cohort of
patients with clinically isolated syndrome. In two independ-
ent databases, MSBase (2403 cases) and the Swedish MS
Registry (556 cases), the authors confirmed a similar propor-
tion of aggressive multiple sclerosis of 6%. Predictors for
aggressive multiple sclerosis were age at onset 535 years,
an EDSS of 53.0 and pyramidal symptoms within the first
year.
We tried to replicate the results of Malpas et al. within the
data of the German MS Registry (GMSR), a nationwide
registry including 430 000 patients (with at least one fol-
low-up since 2014) recruited from all sectors of care in over
190 centres.
By applying an interval-censored proportional hazards
model, the estimated overall rate of aggressive multiple scler-
osis in our GMSR cohort was 8.9% for all patients (includ-
ing progressive cases; n = 17 071; Fig. 1) and 7.0% if only
including patients with relapsing course at onset, which is
similar to previous studies. In univariate analysis of baseline
covariates, age at onset [per 10 years with a hazard ratio
(HR) of 2.02 and 95% confidence interval (CI) (1.91–2.14),
P5 0.001], the first year EDSS [per EDSS; HR: 3.45
(2.74–4.33), P50.001] and pyramidal symptoms within
the first year [HR: 4.51 (3.75–5.43), P50.001] were associ-
ated with aggressive multiple sclerosis in RRMS. In multi-
variable analyses, however, only the EDSS after the first year
and age at onset remained to be statistically significant for
predicting an unfavourable course of multiple sclerosis.
Our data overall support the analysis of Malpas et al. and
similar results were obtained when progressive patients were
included. The progressive course per se had been identified
as a risk factor for aggressive multiple sclerosis and affected
patients should not be excluded unless specifically investigat-
ing forms of aggressive relapsing remitting multiple sclerosis
(ARMS) (Iacobaeus et al., 2020). The ECTRIMS Focused
Workshop Group further points out that a plethora of defi-
nitions of aggressive multiple sclerosis exist and there is no
generally accepted definition in the literature.
We have therefore carried out further analyses of GMSR
data, comparing the results for different published aggressive
multiple sclerosis or highly active multiple sclerosis
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definitions (Gholipour et al., 2011; Freedman and Rush,
2016; Menon et al., 2017; Dı́az et al., 2019; Tintore et al.,
2019; Malpas et al., 2020; Spelman et al., 2020). These defi-
nitions vary, in part considerably, regarding the parameters
to be evaluated (in addition to EDSS, also relapses, MRI
data, therapy response and the follow-up time needed):
(i) Freedman and Rush (2016)/Dı́az et al. (2019) (fulfilment of at
least one criterion within first 5 years of multiple sclerosis): 52
relapses with incomplete recovery within 12 months; 52 MRI
with new or enlarging T2 lesions or gadolinium enhancing
(GD + ) lesions during 12 months on DMT; no treatment effect
during first year of DMT; and confirmed EDSS 5 4.0 after 5
years of disease onset.
(ii) Gholipour et al. (2011)/Menon et al. (2017): confirmed EDSS
5 6.0 after 5 years of symptom onset.
(iii) Spelman et al. (2020) [highly active (HA) multiple sclerosis; we
considered fulfilment any HAMS indication within first 5 years
as aggressive multiple sclerosis comparator]: 52 relapses within
12 months; 51 GD + lesion(s); and 59 T2 lesions (not used
since 59/59 T2 not assessable).
(iv) Tintore et al. (2019)/Malpas et al. (2020): confirmed EDSS 5
6.0 within 10 years of symptom onset; and RRMS: as a study
inclusion criterion, not part of the aggressive multiple sclerosis
definition.
Similar to Malpas et al., only some of our patients could be
classified and analysed in the GMSR, since, depending on
the definition, certain prerequisites regarding follow-up were
required, e.g. in Freedman and Rush (2016)/Dı́az et al.
(2019), and Spelman et al. (2020) (n = 752), accurate data
in the first 5 years after disease onset. For criteria based ex-
clusively on sustained and confirmed EDSS, we considered it
sufficient to observe the end of the follow-up period, which
leads to different numbers of patients being analysed for each
definition. The proportion of aggressive multiple sclerosis/
highly active patients varies significantly between the different
definitions from 4.0% to 23.1% (Table 1 and Fig. 1A).
Direct comparisons of various criteria showed that there is
little overlap between some definitions. For example, only
1% of our patients met the aggressive multiple sclerosis/high-
ly active criteria of the three definitions of Spelman et al.
(2020), Freedman and Rush (2016)/Dı́az et al., (2019), and
Gholipour et al. (2011)/Menon et al. (2017) (Fig. 1B). In
addition to clinical criteria such as relapses and EDSS, we
tried to sharpen the clinical relevance of these definitions and
have therefore included work ability. In this regard, the dif-
ferent definitions showed large variability within aggressive/
highly active multiple sclerosis, ranging from 8.5% to 41.1%
of patients who were not able to work (Table 1), with the
highest numbers for those definitions based on EDSS.
In summary, the term ‘aggressive multiple sclerosis’ or
‘highly active multiple sclerosis’ is used differently in the lit-
erature and no agreement between multiple sclerosis experts
exists on the criteria. Using the term should be carefully
Figure 1 Aggressive multiple sclerosis according to various definitions. (A) Proportions of aggressive multiple sclerosis (MS) patients
over time according to different definitions. In this interval-censored Cox model, the rising proportions of patients in the GMSR classified as ag-
gressive multiple sclerosis according to the definitions of Freedman and Rush (2016), Dı́az et al. (2019), Spelman et al. (2020), Gholipour et al.
(2011), Menon et al. (2017), Tintore et al. (2019) and Malpas et al. (2020) (10 years) were presented depending on the disease duration from
symptom onset. Additionally, the proportion of early retired patients in the first 5 years is given. (B) Venn diagram showing overlapping propor-
tions of aggressive multiple sclerosis patients according to various definitions in the first 5 years of the disease (n = 752). Comparison of aggres-
sive multiple sclerosis patients according to Freedman and Rush (2016) (F) Dı́az et al. (2019), Gholipour et al. (2011) (G) Menon et al. (2017),
Spelman et al. (2020) (S) and the early retired (ER) patients with aggressive multiple sclerosis.
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considered, taking into account the fact that there was little
overlap among the known definitions for aggressive multiple
sclerosis, even when the same dataset is used. Although it
may be plausible to distinguish between a (short-term) re-
lapse and MRI-based highly active multiple sclerosis and a
long-term EDSS-based aggressive multiple sclerosis, we be-
lieve that patient-relevant outcomes, such as ability to work,
may sharpen the meaningfulness of the definition.
We do not doubt the ability of the definitions to identify
aggressive patients, but we believe that three aspects must be
distinguished. First, there is a need to identify patients with
rapid progression of the disease due to risk factors at an
early stage (aggressive multiple sclerosis). Second, there is a
need for long-term results that validate which patients have
a high degree of disability or malignant course, e.g. meas-
ured by EDSS, as in Tintore et al. (2019) and Malpas et al.
(2020). Third, it is necessary to continuously assess the se-
verity of the disease (highly active multiple sclerosis). Well-
defined definitions should be developed for all of these
aspects. In addition, non-clinical factors, such as early retire-
ment, would be important to better assess and predict the
patient’s status. A scoring system that includes several of the
above-mentioned parameters could be helpful in predicting
long-term outcomes and enabling evidence-based treatment
decisions in the future.
Data availability
Anonymized data will be made available on request by any
qualified investigator under the terms of the registries’ usage
and access guidelines and subject to informed consent of the
patients.
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Dı́az et al. (2019)
First 5 years covered
Spelman et al. (2020)
First 5 years covered
Gholipour et al.
(2011)/Menon et al.
(2017) at 5 years
Tintore et al. (2019)/




Patients, n 752 752 4605 3949 4605
n with agMS 174 141 185 331 525
Proportion with agMS, % 23.1 18.8 4.0 8.4 11.4
Female, % 70.7 (63.3–77.3) 73.0 (64.9–80.2) 61.6 (54.2–68.7) 58.6 (53.1–64.0) 67.4 (63.2–71.4)
Progressive onset, % 5.7 (2.8–10.3) 0.7 (0.0–3.9) 22.2 (16.4–28.8) 13.3 (9.8–17.4) 7.8 (5.7–10.4)
Mean age at MS onset 39.0 (37.1–40.8) 33.6 (31.7–35.5) 45.0 (43.3–46.7) 40.7 (39.5–41.9) 41.7 (40.8–42.5)
Mean EDSS, last follow-up 3.5 (3.2–3.8) 2.1 (1.8–2.4) 6.6 (6.5–6.7) 6.7 (6.6–6.8) 3.9 (3.8–4.1)
Retired early, % at 5 years 23.0 (17.0–30.0) 8.5 (4.5–14.4) 41.1 (33.9–48.5) 29.0 (24.2–34.2)
Descriptive statistics are presented as mean (95% confidence intervals). Clopper-Pearson variants for proportions. agMS = aggressive multiple sclerosis; EDSS = Expanded
Disability Status Scale; GMSR = German Multiple Sclerosis Registry; MS = multiple sclerosis.
Letter to the Editor BRAIN 2020: 143; 1–4 | e97
Celgene, Merck and Novartis. None resulted in a conflict of
interest. C.W. has received institutional support from
Novartis, Sanofi-Genzyme, Biogen, and Roche. None
resulted in a conflict of interest. P.S.R. has received speaking
fees, honoraria from advisory boards, and/or financial sup-
port for research activities from AbbVie, Amicus, Biogen,
Daiichi-Sankyo, Merck Serono, Novartis, Roche, Sandoz,
Sanofi Genzyme, and Teva. None resulted in a conflict of
interest. U.K.Z. has received speaking fees, travel support
and/or financial support for research activities from
Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche,
Sanofi Genzyme, Teva as well as EU, BMBF, BMWi and
DFG. None resulted in a conflict of interest. All other
authors report no competing interests.
References
Dı́az C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an up-
date. Mult Scler Relat Disord 2019; 30: 215–24.
Freedman MS, Rush CA. Severe, highly active, or aggressive multiple
sclerosis. Continuum (Minneap Minn) 2016; 22: 761–84.
Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T.
Demographic and clinical characteristics of malignant multiple scler-
osis. Neurology 2011; 76: 1996–2001.
Iacobaeus E, Arrambide G, Pia Amato M, Derfuss T, Vukusic S,
Hemmer B, et al. Aggressive multiple sclerosis (1): towards a defin-
ition of the phenotype. Mult Scler 2020; 12: 1352458520925369.
Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D,
Havrdova EK, et al. Early clinical markers of aggressive multiple
sclerosis. Brain J Neurol 2020; 143: 1400–13.
Menon S, Zhu F, Shirani A, Oger J, Freedman MS, Tremlett H.
Disability progression in aggressive multiple sclerosis. Mult Scler
2017; 23: 456–63.
Spelman T, Freilich J, Anell B, Wong SL, Hillert J. Patients with high-
disease-activity relapsing-remitting multiple sclerosis in real-world
clinical practice: a population-based study in Sweden. Clin Ther
2020; 42: 240–50.
Tintore M, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Rı́o
J, Tur C, et al. The long-term outcomes of CIS patients in the
Barcelona inception cohort: looking back to recognize aggressive
MS. Mult Scler 2019; 1352458519877810. doi:
10.1177/1352458519877810.
e97 | BRAIN 2020: 143; 1–4 Letter to the Editor
